Custom service
Monoclonal Antibody Production
From immunisation to a stable, isotyped, sequence-defined hybridoma.
A monoclonal antibody is only as good as the fusion it came from. Most of the work that determines outcome happens before the first 96-well plate is read: antigen quality, the choice of adjuvant, the interval between boosts, and the decision of when to take the spleen. Our protocol is conventional in outline and uncompromising in those details.
BALB/c or C57BL/6 mice are immunised with 25–50 µg of antigen per injection, four to five times at two- to three-week intervals, with a final intravenous or intraperitoneal boost three days before fusion. Splenocytes are fused to SP2/0 myeloma cells with PEG 1500, and plated into 96-well plates under HAT selection at a density calibrated so that most positive wells contain a single clone.
Screening is run against your antigen in your format — ELISA, cell-based flow, or a functional assay — with a carrier-only and a mock-transfected control on every plate. Parent positives are subcloned twice by limiting dilution, expanded, isotyped and frozen. What you receive is a clonal line, not a mixed well that will drift after three passages.
Service Highlights
Where it fits
Standard monoclonal production remains the most cost-effective route to a durable reagent: ELISA pairs, Western blot antibodies, immunohistochemistry clones and flow cytometry panels. Once a hybridoma exists, the reagent can be reproduced indefinitely at predictable cost, which is why it still dominates catalogue antibody supply.
It is not the fastest route — RIMMS or B cell sorting reach an antibody sooner — and it fails against antigens that are toxic, non-immunogenic or conserved between mouse and human. For those, genetic immunisation, peptide display or recombinant library approaches are the better entry point.
Documentation and QC
Each campaign is delivered with a fusion report, screening data for every plate, subcloning records, isotype confirmation, and a frozen cell bank with passage numbers. Antibody concentration is measured by A280 or BCA, purity by SDS-PAGE under reducing and non-reducing conditions, and endotoxin is tested for any batch intended for in vivo work.
Frequently asked questions
How many clones will we receive?
Typically two to five, selected from the strongest and most specific parent wells. If the campaign yields only one usable clone we will tell you and discuss whether a second fusion is warranted, rather than delivering a weak panel.
Can the hybridoma be adapted to serum-free culture?
Yes. We routinely adapt clones to serum-free, low-protein medium over four to six passages, which simplifies downstream purification and reduces bovine IgG contamination.
Do you guarantee performance in a specific application?
We guarantee binding to the immunogen as measured in the agreed screening assay. Application-specific validation, such as IHC on formalin-fixed tissue, is offered as an additional work package because it often requires a different clone than ELISA does.
Send the antigen with a short note on the application. If the target is one where a hybridoma campaign is unlikely to succeed, we will propose a different route before the project begins.
Service Highlights
- Antigen QC first. Purity, endotoxin and aggregation are checked before immunisation; an aggregated antigen produces a strong response to the aggregate, not to your protein.
- Parallel animals. Three to five mice per campaign, screened independently so that a non-responder does not consume the whole timeline.
- Your assay as primary screen. We screen in the format you will use, because an antibody that works only in a plate-coating ELISA often fails in flow.
- Two rounds of cloning. Limiting dilution at 0.5 cells per well, with a documented monoclonality check by isotype and by sequence where required.
- Isotype and chain analysis. IgG1, IgG2a, IgG2b, IgG3, IgM, IgA and kappa/lambda determined by commercial isotyping strips.
- Sequence on request. VH/VL recovered by RT-PCR and Sanger sequencing, so the clone can be reformatted or re-expressed recombinantly later.
How the work runs
Antigen and assay review
We agree on the immunogen, the screening antigen and the positive control before any animal is injected. Where a control does not exist, one is generated or the screening strategy is redesigned.
Immunisation and monitoring
Four to five injections at two- to three-week intervals, with test bleeds from week six. Serum titre is measured by ELISA and the animal with the best titre and specificity goes forward.
Fusion
Splenocytes fused with SP2/0 at a 5:1 ratio, distributed across 20–40 plates, and maintained under HAT selection for ten to fourteen days.
Primary and confirmatory screening
Supernatants are screened against antigen, carrier and mock controls. Positives are re-tested after expansion, and cross-reactivity panels are run where the target has homologues.
Subcloning
Two rounds of limiting dilution, with the second round confirming stability of the isotype and of the binding signal.
Banking and characterisation
Cells are expanded, mycoplasma-tested and frozen at 10–20 vials. Isotype, concentration, SDS-PAGE purity and binding curve are reported.
Specifications & timeline
- Timeline
- 10–14 weeks — to subcloned hybridoma
- Screening
- ≥1,000 — wells per fusion
- Yield
- 1–10 mg/mL — in culture supernatant
- Timeline
- 10–14 weeks: immunisation 8–10 weeks, fusion and screening 3–4 weeks
- Host species
- Mouse (BALB/c, C57BL/6); rat and hamster available
- Antigen amount
- 100–200 µg per campaign, 25–50 µg per injection
- Plates per fusion
- 20–40 × 96-well, typically 1,000–3,000 wells screened
- Deliverables
- 2–5 subcloned hybridomas, isotype report, supernatant, frozen cell bank, sequence on request
- Scale-up options
- In vitro culture, hollow-fibre bioreactor, or ascites
Related Products
- Recombinant ProteinsGrowth factors, cytokines and antigens produced across E. coli, yeast, insect and mammalian hosts — over 10,000 items on the shelf and ready to move.
- Native ProteinsIsolated directly from natural sources, preserving native post-translational modifications and conformational epitopes that recombinant systems can miss.
- Monoclonal AntibodiesRecombinant and hybridoma clones characterised for Western blot, IHC, immunofluorescence, ELISA and flow cytometry — application data included.
Next step
Tell us the target, we will tell you what is feasible
Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.